Creo Medical Group PLC Notice of results and investor briefing (4892T)
March 21 2019 - 3:02AM
UK Regulatory
TIDMCREO
RNS Number : 4892T
Creo Medical Group PLC
21 March 2019
Creo Medical Group plc
("Creo" or the "Company")
Notice of results and investor briefing
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, will announce
its final results for the 18 month period to 31 December 2018 on
Friday 5 April 2019.
Investor briefing
A briefing for investors will take place on Tuesday 9 April 2019
at the Brand Exchange, 3 Birchin Lane, EC3V 9BW at 5.15pm for a
5.30pm start and will be followed by refreshments. If you would
like to register, please contact Walbrook PR on 020 7933 8780 or
email creo@walbrookpr.com
- Ends -
For further information please contact:
Creo Medical Group plc
Richard Rees (CFO) +44 (0)129 160 6005
Cenkos Securities +44 (0)20 7397 8900
Stephen Keys / Mark Connelly (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Helen Cresswell Mob: +44 (0)7841 917 679
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and RF energy to surgical endoscopy. Creo has
developed CROMA, an electrosurgical advanced energy platform that
combines bipolar radiofrequency for precise localised cutting and
microwave for controlled coagulation. This technology provides
clinicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA platform to market
through a suite of medical devices which the Company has designed,
initially for the emerging field of GI therapeutic endoscopy, an
area with high unmet needs. The CROMA platform will be developed
further for bronchoscopy and laparoscopy procedures. The Company
believes its technology can impact the landscape of surgery and
endoscopy by providing a safer, less-invasive and more
cost-efficient option of treatment.
For more information about Creo Medical please see our website,
investors.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORZMGZFKGRGLZM
(END) Dow Jones Newswires
March 21, 2019 03:02 ET (07:02 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024